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Patient 1 10 172.2 27 FEIBA: 4500 IU (50-60 IU/Kg) 3 times per
week.
4 months later: 5500 IU (70 IU/Kg) 2 times per
week.
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The development of antibodies to factor
VIII is one of the most serious
complications of hemophilia occurring in 20
– 30% of severe hemophilia A patients.
Although these patients have some degree
of bleeding, a small subset suffers more
ResultsIntroduction
Patient 2 11 80 41 FEIBA: 5000 IU (50 IU/Kg) 2 times per week.
18 months after: 6000 IU (60 IU/Kg) 2 times
per week.
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severe hemorrhagic complications such as
life threatening bleeds or bleeding into the
cranium or peritoneal space.
Secondary prophylaxis has been
demonstrated to be a good alternative to
on-demand therapy in hemophilia patients
without inhibitors in reducing bleeding
episodes and hospitalization or
absenteeism from work.
The evidence of the benefits of secondary
prophylaxis in inhibitor patients with
bypassing agents is more limited.
Hemophilic patients with inhibitors have a higher risk of morbidity
and mortality associated with bleeding episodes, but the
availability of bypassing agents, such as FEIBA and rFVIIa,
suggests that these patients can have the same benefits from
prophylactic treatment as those without inhibitors. Prophylaxis isMaterial and Methods
Conclusion
Hemorrhages Days of absence of work
Patient 1 1 hemarthrosis
5 severe muscle hematomas
Not available
Patient 2 7 hemarthrosis
4 muscle hematomas
2 severe bleedings into the 
peritoneal space
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In the year before
In the year before In the year after
Patient 1 206 763.53 € 257 975.13 €
Patient 2 732 376.47 € 529 638.9 €
Costs (with IVA)
Hemorrhages Days of absence of work
Patient 1 1 traumatic tongue 
hematoma
Not available
Patient 2 8 hemarthrosis 61
We reviewed two cases of adult hemophilia
A patients with a high responder inhibitor
to factor VIII who started prophylactic
treatment with FEIBA after several
episodes of muscle haematomas and
major bleeding into the peritoneal space in
the previous year. We evaluated the
number and type of bleeding episodes one
year before and after the start of
prophylaxis, the quality of life assessed by
the number of working days and ability to
participate in normal activities, and
compared the costs of prophylactic
treatment per year with on-demand
therapy.
usually an expensive treatment, however we could observe that
the costs were not much higher in patient 1, and in patient 2 there
was a reduction in the expenses compared with treatment on-
demand in the year before. We also observed an important
reduction in the number and severity of hemorrhagic events in
both cases and the number of days of absence of work were
much lesser (patient 1 works at home and these numbers are not
available, but the fact that he had several hospital stays in the
year before prophylaxis and none in the year after were taken into
account). We could also observe that this type of treatment also
contributed to a better quality of life of these patients.
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